← Quidel overview

Quidel vs West Pharmaceutical Services: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Quidel Corporation (QDEL)

Q3 2026
▼3▲1

QuidelOrtho slashes 2026 outlook on China and respiratory weakness

  • 2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.

    The guidance cut is the single biggest new force pushing QDEL down this period.

  • China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.

    These are the specific demand problems management blamed for the guidance cut.

  • Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.

    It shows how professional valuations were reset lower after the guidance cut.

  • Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.

    It is the main potential upside counterweight to the weak guidance.

August 2026
▼3▲1

QuidelOrtho slashes 2026 outlook on China and respiratory weakness

  • 2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.

    The guidance cut is the single biggest new force pushing QDEL down this period.

  • China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.

    These are the specific demand problems management blamed for the guidance cut.

  • Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.

    It shows how professional valuations were reset lower after the guidance cut.

  • Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.

    It is the main potential upside counterweight to the weak guidance.

Latest
▼3▲1

QuidelOrtho slashes 2026 outlook on China and respiratory weakness

  • 2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.

    The guidance cut is the single biggest new force pushing QDEL down this period.

  • China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.

    These are the specific demand problems management blamed for the guidance cut.

  • Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.

    It shows how professional valuations were reset lower after the guidance cut.

  • Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.

    It is the main potential upside counterweight to the weak guidance.

West Pharmaceutical Services Inc (WST)

Q3 2026
▲1

West Pharmaceutical Surges on GLP-1 and Biologics Demand, Raises Guidance

  • Q2 Earnings Beat and Raised Guidance West Pharmaceutical reported Q2 revenue of $872.3 million, up 13.8%, and adjusted EPS of $2.37, beating estimates. Management raised full-year revenue and EPS guidance, signaling confidence. This directly boosts investor expectations and supports a higher stock price.

    This is the most recent and concrete positive catalyst, showing strong financial performance and improved outlook.

July 2026
▲1

West Pharmaceutical Surges on GLP-1 and Biologics Demand, Raises Guidance

  • Q2 Earnings Beat and Raised Guidance West Pharmaceutical reported Q2 revenue of $872.3 million, up 13.8%, and adjusted EPS of $2.37, beating estimates. Management raised full-year revenue and EPS guidance, signaling confidence. This directly boosts investor expectations and supports a higher stock price.

    This is the most recent and concrete positive catalyst, showing strong financial performance and improved outlook.

Latest
▲1

West Pharmaceutical Surges on GLP-1 and Biologics Demand, Raises Guidance

  • Q2 Earnings Beat and Raised Guidance West Pharmaceutical reported Q2 revenue of $872.3 million, up 13.8%, and adjusted EPS of $2.37, beating estimates. Management raised full-year revenue and EPS guidance, signaling confidence. This directly boosts investor expectations and supports a higher stock price.

    This is the most recent and concrete positive catalyst, showing strong financial performance and improved outlook.